Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
101 hedge funds and large institutions have $612M invested in Syros Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 16 closing their positions.
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
51% more capital invested
Capital invested by funds: $406M → $612M (+$206M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
31% more call options, than puts
Call options by funds: $1.7M | Put options by funds: $1.3M
24% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 29
9% more funds holding
Funds holding: 93 → 101 (+8)
8.79% less ownership
Funds ownership: 100.59% → 91.8% (-8.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$52.8M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$14.3M |
| 3 |
O
OrbiMed
New York
|
+$14.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.13M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$7.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$19.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.87M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.82M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.47M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$683K |
SYRS Hedge Fund Activity: Q4 2020 in Review
101 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2020, worth a combined $612M — up 51% from $406M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SYRS positions and 16 closed out — a net gain of 9 holders — while 36 added to existing stakes and 29 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $52.8M. The largest seller was ARK Investment Management, cutting an estimated $19.8M.
- 101 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2020, up from 93 in Q3 2020.
- Funds reported $612M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 51% quarter-over-quarter.
- 25 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 16 closed out, a net change of +9 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Bain Capital Life Sciences Investors, an estimated $52.8M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was ARK Investment Management, an estimated $19.8M sold.
Based on aggregated 13F filings for Q4 2020.